

Hydrogen Sulfide, the Next Potent Preventive and Therapeutic Agent in Aging and Age-Associated Diseases

Yuan Zhang, Zhi-Han Tang, Zhong Ren, Shun-Lin Qu, Mi-Hua Liu, Lu-Shan Liu, Zhi-Sheng Jiang

Institute of Cardiovascular Disease and Key Lab for Arteriosclerosis of Hunan Province, University of South China, Hengyang City, Hunan Province, People's Republic of China

Hydrogen sulfide (H₂S) is the third endogenous signaling gasotransmitter, following nitric oxide and carbon monoxide. It is physiologically generated by cystathionine-γ-lyase, cystathionine-β-synthase, and 3-mercaptopyruvate sulfurtransferase. H₂S has been gaining increasing attention as an important endogenous signaling molecule because of its significant effects on the cardiovascular and nervous systems. Substantial evidence shows that H₂S is involved in aging by inhibiting free-radical reactions, activating SIRT1, and probably interacting with the age-related gene *Klotho*. Moreover, H₂S has been shown to have therapeutic potential in age-associated diseases. This article provides an overview of the physiological functions and effects of H₂S in aging and age-associated diseases, and proposes the potential health and therapeutic benefits of H₂S.

Aging has been a topic of great interest to the scientific community for a long time. This biological process is characterized by time-dependent progressive decline of physiological functions accompanied by increased incidence of age-associated diseases. The basic cellular and biochemical features of aging are very complex to elucidate clearly. Although various theories have been proposed to explain the process of aging, there is none that has been generally accepted by gerontologists. Denham Harman proposed that aging and age-associated diseases are basically caused by the deleterious side attacks of free radicals on cell constituents and connective tissues (1). This proposal, which implies that limiting or inhibiting the formation of free radicals could reduce the rate of aging and prevent age-associated diseases, is receiving growing acceptance as a possible explanation of the aging theory. Studies showing that nutritional antioxidants (vitamin C, vitamin E, and resveratrol) and antioxidant enzymes (superoxide dismutase [SOD], catalase [CAT], and glutathione [GSH] peroxidase) can promote better health and longevity by suppressing free-radical reactions are still limited and equivocal (2). However, antioxidants are receiving considerable attention and their use is increasingly being adopted in Western countries. Hydrogen sulfide (H₂S), which was previously regarded as a poisonous gas, is generated endogenously in mammals. With its antioxidant and other physiological functions, it has the potential to provide many health benefits. Several studies have shown that H₂S prevents free radical-induced impairment and is beneficial in treating age-associated diseases. A recent study reported that the plasma H₂S level in humans over 50 to 80 years of age declines with age (3). However, the precise relationship between H₂S and physiological changes that constitute aging is largely unknown. This review aims to provide detailed information on the various physiological effects of H₂S on aging and age-associated diseases known to date.

GENERATION OF ENDOGENOUS H₂S

H₂S is a colorless, flammable, water-soluble gas with the characteristic smell of rotten eggs. In the past several centuries, H₂S had been known only for its toxicity and environmental hazards. However, as a member of a family of gasotransmitters that includes nitric oxide and carbon monoxide, it is produced endogenously in mammals, including humans, and has important phys-

iological roles in the human body (4, 5). Previous studies reported that H₂S is physiologically generated by cystathionine-γ-lyase (CSE) and cystathionine-β-synthase (CBS) (6, 7). These two pyridoxal-5'-phosphate-dependent enzymes, which are expressed in the liver, kidney, brain, thoracic aorta, ileum, pancreatic islets, uterus, and placenta, among other locations, are crucial in the synthesis of H₂S (8–13). CBS is predominantly expressed in the brain and the nervous system (6, 14, 15). However, expression of CSE proteins has been mainly observed in vascular smooth muscle cells and in the heart (16, 17). In addition, 3-mercaptopyruvate sulfurtransferase and cysteine aminotransferase localized to the endothelium of the thoracic aorta have also been reported to produce H₂S from cysteine and alpha-ketoglutarate (18) (Fig. 1).

PHYSIOLOGICAL EFFECTS OF ENDOGENOUS H₂S

H₂S has various physiological effects on the human body. First, H₂S is a major endothelium-derived hyperpolarizing factor (EDHF) that causes hyperpolarization and vasorelaxation of vascular endothelium and smooth muscle cells by activating ATP-sensitive, intermediate-conductance and small-conductance potassium channels through cysteine S-sulfhydration (19, 20). Second, H₂S can prevent cytokine- or oxidant-induced oxidative damage through its antioxidative effects (21–23). Additionally, H₂S can inhibit the expression of proinflammatory factors by downregulating NF-κB activation or by upregulating heme oxygenase 1 expression (24–28). Moreover, H₂S may help regulate various functions of the human body with its cytoprotective, antifibrotic, antiapoptotic, and angiogenic properties (29–32). Taken together, these known functions of H₂S imply an important role in aging and age-associated diseases (Table 1).

Published ahead of print 7 January 2013

Address correspondence to Zhi-Sheng Jiang, zsjianglab@yahoo.cn.

Y.Z. and Z.-H.T. are co-first authors.

Copyright © 2013, American Society for Microbiology. All Rights Reserved.

doi:10.1128/MCB.01215-12




FIG 1 Generation of endogenous H₂S. H₂S is synthesized by two cytosolic pyridoxal-5'-phosphate-dependent enzymes responsible for the metabolism of L-cysteine, namely, cystathionine-β-synthase (CBS) and cystathionine-γ-lyase (CSE), as well as by the combined action of 3-mercaptopyruvate sulfoxidase (3-MST) and cysteine aminotransferase (CAT).

ROLE OF H₂S IN REGULATION OF AGING

H₂S inhibits free-radical reactions and oxidative stress. Continuous accumulation of deleterious free-radical reactions in cells and tissues is a major contributor to aging. Hence, the aging process may be caused by free-radical reactions. Free radicals and oxidative stress are believed to be important risk factors in aging and various age-associated diseases. A judicious selection of diet and antioxidant supplements is expected to promote longevity (34, 35). Consistent with this idea, many healthy volunteers with improved body redox status benefit from sulfurous water consumption, which can reduce biomolecule oxidation and provide valid protection against oxidative damage commonly associated with aging and age-related degenerative diseases. However, endogenously produced H₂S can be hydrolyzed to hydrosulfide and sulfide ions. Interestingly, it has been reported that levels of both lipid and protein oxidation products, namely, malondialdehyde (the lipid peroxidation product), advanced oxidation protein products, and carbonyls decrease significantly in plasma samples of healthy volunteers subjected to a cycle of hydroponic therapy with H₂S-rich water (500 ml day⁻¹ for 2 weeks) (36). Although the underlying mechanisms of this effect are not completely understood, it implies that H₂S can protect against oxidative stress. Oxidative damage to biological macromolecules is caused by increased levels of free radicals, reactive oxygen species (ROS), and reactive nitrogen species (RNS) which can disrupt the cellular reduction-oxidation (redox) balance. The primary ROS/RNS species generated in a cell are superoxide (O₂^{•-}), hydrogen peroxide (H₂O₂), and nitric oxide (NO[•]) (37). H₂S can protect mouse brain endothelial cells (bEnd3) from methionine (Met)-induced oxidative stress and cytotoxicity. Pretreatment of bEnd3 cells with NaHS (0.05 mM) can decrease H₂O₂, peroxynitrite (ONOO⁻), and O₂^{•-} generation induced by Met. In the ROS scavenging pathway, SOD converts O₂^{•-} to H₂O₂, which is subsequently reduced to H₂O and O₂ by CAT. However, low concentrations of H₂S can

synergistically increase inhibitory effects of apocynin, *N*-acetyl-L-cysteine (NAC), reduced GSH, CAT, SOD, and *N*ω-nitro-L-arginine methyl ester (L-NAME) on ROS production and redox enzyme levels induced by Met (38). ONOO⁻, a powerful oxidant and cytotoxic species which can induce nitration of tyrosine and tyrosine residues in proteins, is formed from rapid interaction of NO[•] and O₂^{•-} (39). H₂S has also been considered a potent scavenger of ONOO⁻. H₂S at low concentrations (30 μM) can significantly inhibit tyrosine nitration mediated by ONOO⁻ to an extent similar to that seen with reduced GSH, a major antioxidant in the cellular defense against oxidative stress. Additionally, H₂S can also significantly inhibit cytotoxicity mediated by ONOO⁻ in human neuroblastoma SH-SY5Y cells at physiological levels (40). In addition, Whiteman et al. have shown that H₂S can similarly quench NO[•] to form a novel nitrosothiol compound *in vitro*. This suggests that H₂S has direct chemical interactions with NO[•] free radicals to suppress oxidative stress (41). Moreover, Kimura et al. demonstrated that H₂S can protect mouse brain neuroblastoma Neuro2a cells from oxidative stress caused by H₂O₂ and recover GSH levels suppressed by H₂O₂ in those cells (42). Furthermore, modulation of oxidative stress by calorie restriction (CR) is recommended as one mechanism to slow the aging process and decline of body functions in animals (43). Thus, H₂S may also slow the aging process by inhibiting free-radical reactions and oxidative stress.

The free-radical theory was revised when mitochondria were found to be responsible for the initiation of most free-radical reactions occurring in cells. The life span is also postulated to be determined by the rate of free-radical damage to mitochondria. In fact, owing to continuous generation of free radicals throughout the life of a cell, mitochondria, especially mitochondrial DNA, are the key targets of free-radical attack (44). Kimura and coworkers showed that H₂S reduces cystine to cysteine in the extracellular space and increases intracellular concentrations of cysteine to increase the production of intracellular GSH and enhances the redistribution of GSH into mitochondria in Neuro2a cells. It enables H₂S to suppress oxidative stress in the mitochondria (42). In rat models of ischemia and reperfusion (I/R) injury, it has been observed that preconditioning with H₂S can prevent mitochondrial dysfunction in rat intestinal mucosa by a calcium-activated, large-conductance potassium channel-dependent mechanism (45). Under I/R conditions, production of ROS increases, which has a pivotal role in the pathogenesis of myocardial I/R injury. Inhibition of oxidative stress has been reported to underlie the

TABLE 1 Physiological effects of hydrogen sulfide on aging

Parameter	Effect ^a		References
	Aging	H ₂ S	
Blood pressure	↑	⊥	19, 20
Oxidative damage	↑	⊥	21, 22, 23
Inflammation			
Inducible NO synthase	↑	⊥	24, 25, 26, 27, 28
NF-κB activation	↑	⊥	
Heme oxygenase 1	↓	↑	
Apoptosis	↑	⊥	30, 33

^a ↑, increase; ↓, decrease; ⊥, blunting of the increase.

cardioprotective effects of H₂S under I/R conditions. Sun et al. showed that treating cardiomyocytes with 50 μ M NaHS, which is close to the level found in rat plasma, decreases the levels of ROS by inhibiting mitochondrial complex IV3 and increasing SOD activities in cardiomyocytes under I/R conditions. H₂S has also been found to inhibit electron transport to reduce harmful ROS generation under cardiac I/R conditions (46). Thus, protection against oxidative stress-induced mitochondrial damage may be a novel mechanism through which H₂S could furnish valid protection and possibly increase life span.

H₂S activates SIRT1 to resist aging. The silent information regulator 2 gene (*SIR2*) family, which is conserved from prokaryotes to eukaryotes (*Staphylococcus aureus*, fission yeast, *Arabidopsis*, *Caenorhabditis elegans*, mouse, rat, human), has functions in silencing, cell cycle progression, and chromosome stability (47). *SIR2* is a determinant of life span in yeast mother cells. It can promote longevity in *Saccharomyces cerevisiae* by suppressing the generation and accumulation of extrachromosomal ribosomal DNA (rDNA) circles, which are considered a cause of aging in yeast (48). Similarly, it has been demonstrated that *SIR2*, which encodes a histone deacetylase, extends the life span of *Caenorhabditis elegans* through signaling pathways involving *DAF-2*/insulin receptor and *DAF-16/FOXO* (49, 50). Mammals have seven Sir2 homologues (SIRT1 to -7), of which SIRT1 is most closely related to Sir2. These proteins have a highly conserved NAD-dependent sirtuin core domain, first identified in the yeast Sir2 protein, making them good candidates for life span regulators (51). Interestingly, it has been reported that exogenous H₂S has a protective effect on maintaining the circadian rhythm of clock genes in isolated hepatocytes by changing the NAD⁺/NADH ratio and enhancing the activity of SIRT1 protein (52). SIRT1 has thus emerged as a major life span regulator, and H₂S has been hypothesized to delay aging, in part by activating SIRT1.

Calorie restriction is the only established antiaging experimental paradigm in a variety of species, including mammals, flies, nematodes, and yeast, that has been accepted by many researchers. It has been reported that CR can extend life span by increasing Sir2 activity and activating Sir2 deacetylase in yeast and *Drosophila*. Additionally, the expression of mammalian Sir2 (SIRT1) is induced in calorie-restricted rats and also in human cells cultured in the presence of serum from such rats. SIRT1 can deacetylate the DNA repair factor Ku70, causing it to sequester the proapoptotic factor Bax away from the mitochondria, thereby inhibiting stress-induced apoptotic cell death. A major cause of aging is perceived to arise from the cumulative effects of cell loss over time. Moreover, it has also been reported that CR can inhibit the insulin/insulin-like growth factor 1 (IGF-1) pathway to increase SIRT1 expression. Thus, CR can promote longevity by inducing SIRT1 expression and promoting long-term survival of irreplaceable cells (33). Correspondingly, when exposed to H₂S, nematodes are apparently healthy and do not exhibit phenotypes consistent with metabolic inhibition. Instead, animals exposed to H₂S are long-lived, and this phenotype requires Sir2 activity, which may translate environmental changes into physiological alterations to improve survival (53). CR also has potential benefits for CSE and CBS in both the aorta and liver by reducing oxidative stress and ameliorating the negative effect of age on H₂S concentration. Consistent with this, Predmore et al. inferred from their study that CR may help maintain the H₂S signaling system during aging (54). CR and H₂S apparently have a synergistic antiaging effect by reg-

ulating SIRT1 activity. Our laboratory recently demonstrated that H₂S has protective effects against human umbilical vein endothelial cell senescence, which may involve the regulation of SIRT1 activity. Similar to resveratrol, H₂S is likely a CR mimetic with potential antiaging functions mediated via SIRT1 activation. It has been reported that SIRT1 could deacetylate the FOXO transcription factors *in vitro* and within mammalian cells to increase cellular stress resistance, which is correlated with extended organismal longevity (55). However, the hypothesis that the antiaging effects of H₂S are mediated via the SIRT1/FOXO pathway needs to be validated with further investigations.

Resveratrol, a polyphenol found in red wine, is a CR mimetic with potential antiaging and antidiabetogenic properties. Resveratrol ameliorates age-related metabolic phenotypes by inhibiting cyclic AMP (cAMP) phosphodiesterases (PDE). Inhibiting PDE4 with rolipram reproduces all the metabolic benefits of resveratrol, including prevention of diet-induced obesity and promotion of mitochondrial function, physical stamina, and glucose tolerance in mice. Therefore, PDE4 inhibitors may also prevent and ameliorate the symptoms of age-related metabolic diseases (56). H₂S also acts as an endogenous inhibitor of phosphodiesterase activity (57). However, whether H₂S uses the same mechanism for inhibiting phosphodiesterases to prevent age-related diseases and for exerting antiaging effects via SIRT1 activation remains unknown. Figure 2 gives an overview of the pathways that underlie the antiaging effects of H₂S.

Effect of H₂S on the age-related gene *Klotho*. The age-related gene *Klotho* suppresses the expression of multiple age-associated phenotypes to extend life span. *Klotho* increases resistance to oxidative stress by activating the FOXO forkhead transcription factors that induce expression of manganese SOD (58). *Klotho* also represses *DAF-2* (insulin/IGF-like) receptors under physiological conditions, thereby inducing derepression of *DAF-16* (FOXO) and subsequent overexpression of factors such as antioxidant enzymes that improve longevity and stress resistance (59).

Klotho is predominantly expressed in the kidney. Downregulation of *Klotho* in the kidneys aggravates the development of renal damage induced by angiotensin II via increased oxidative stress, whereas induction of *Klotho* expression has therapeutic effects against angiotensin II-induced end organ damage (60). Yoon et al. confirmed that angiotensin II plays a pivotal role in regulating expression of *Klotho* in cyclosporine (CsA)-induced renal injury and that an angiotensin II type 1 (AT1) receptor blocker inhibits aging by decreasing CsA-induced oxidative stress (61). Interestingly, H₂S has a direct inhibitory effect on angiotensin-converting enzyme (ACE) activity, which catalyzes the conversion of angiotensin I into angiotensin II (62). Moreover, H₂S can decrease angiotensin II-induced mitogen-activated protein kinase (MAPK) activation, AT1 receptor binding, and the binding affinity of AT1 receptor in a dose-dependent manner (63). In addition, Lu et al. demonstrated that H₂S inhibits renin activity, which participates in the renin-angiotensin system (64). Thus, H₂S may enhance *Klotho* expression via negative regulation of angiotensin II activity. Given these findings, H₂S may be a potent preventive and therapeutic agent in aging and age-associated diseases. Figure 3 summarizes the indirect effects of H₂S on *Klotho* expression to show that H₂S may be involved in regulation of aging through the *Klotho* pathway.




FIG 2 H₂S exerts its antiaging effects by directly inhibiting free radicals and oxidative stress and by upregulating SIRT1 activity. H₂S can directly inhibit the free radicals ROS/RNS and increase inhibitory effects of GSH and SOD on ROS production and redox enzyme levels to increase cellular stress resistance, which is correlated with extended organismal longevity. CR and resveratrol have been reported to have antiaging properties. CR and resveratrol share similar antiaging mechanisms: they both increase SIRT1 expression to inhibit oxidative stress or to play antiapoptotic roles. Resveratrol can also ameliorate age-related metabolic phenotypes by inhibiting cAMP phosphodiesterases (PDE). Similarly, H₂S has been reported to enhance the activity of SIRT1 and to inhibit PDE activity. As shown in the figure, H₂S may have antiaging functions through several shared pathways related to CR and resveratrol.

H₂S: A NOVEL THERAPEUTIC AGENT IN AGE-ASSOCIATED DISEASES?

H₂S has been generally recognized as an important signaling molecule in cardiovascular and nervous systems. Enhancement of the physiological effects of H₂S has been confirmed by understanding the therapeutic implications of H₂S in age-associated diseases, such as cardiovascular system diseases, central nervous system degenerative diseases, diabetes, and cancer, among others (Table 2).

Cardiovascular system diseases. Aging is considered a principal risk factor in the progression of hypertension (81). The plasma concentration of H₂S in spontaneously hypertensive rats is substantially lower than that in normotensive control animals (65). Similarly, the plasma H₂S level and H₂S production are greatly reduced and transcription and activity of CSE in vascular tissues are also obviously inhibited in rats with hypertension induced by N^G-nitro-L-arginine methyl ester (L-NAME). However, H₂S can prevent the development of hypertension induced by L-NAME. This suggests that the H₂S synthase/H₂S pathway participates in the pathogenesis of hypertension (82). The fundamental hemodynamic abnormality in hypertension is increased peripheral vascular resistance (83). It has been reported that H₂S can relax rat aortic tissues *in vitro* in an ATP-sensitive K⁺ (K_{ATP}) channel-

dependent manner and that H₂S at physiologically relevant concentrations induces vasorelaxation via activation of K_{ATP} channels in isolated mesenteric artery smooth muscle cells (17, 84). K_{ATP} channels are activated by binding of its Kir subunits to phosphatidylinositol-4,5-bisphosphate (PIP₂) along with a reduction in binding to the inhibitor ATP (85). H₂S causes vascular endothelial and smooth muscle cell hyperpolarization and vasorelaxation by activating K_{ATP} channels through cysteine S-sulphydration, which can enhance Kir6.1-PIP₂ binding and reduce Kir6.1-ATP binding (19). Additionally, considering that human hypertensive pulmonary vascular disease represents a disease of excessive smooth muscle cell proliferation (86), H₂S could also suppress the proliferation of cultured aortic vascular smooth muscle cells of rats *in vitro* through the MAPK pathway (87). Because H₂S is a major EDHF and a primary determinant of vasorelaxation in numerous vascular beds (20), drugs that alter CSE activity or H₂S-mediated channel sulphydration may be effective therapeutic agents for treating hypertension.

Atherosclerosis, characterized by lesions in large and medium arteries, is the primary cause of coronary artery disease. Not only is this condition a chronic inflammatory disease that can lead to an acute clinical event by plaque rupture and thrombosis, but it is also an inevitable degenerative consequence of aging (88). Athero-




FIG 3 H₂S may have an effect on the age-related gene *Klotho* to promote longevity. *Klotho* can improve longevity by inhibiting IIS signaling, inducing FOXO derepression, and decreasing angiotensin II-induced oxidative stress, among other effects. However, angiotensin II may downregulate the expression of *Klotho*. Interestingly, H₂S exhibits direct inhibitory action on ACE activity, which catalyzes the conversion of angiotensin I to angiotensin II. Moreover, H₂S can decrease the binding affinity between angiotensin II and AT1 receptor and can inhibit renin activity, which participates in the renin-angiotensin system. Hence, H₂S may improve *Klotho* expression to promote longevity via negative regulation of angiotensin II production.

sclerosis is characterized by multiple key events, including endothelial dysfunction, infiltration of monocytes and their differentiation into macrophages, conversion of lesion-resident macrophages into foam cells, and smooth muscle cell proliferation. Fortunately, atherosclerosis can be interrupted by H₂S. Increasing evidence has proven that H₂S plays a significant role in all these biological processes and that disruption of H₂S homeostasis may contribute to the pathogenesis of atherosclerosis (89). For instance, H₂S plays an antiatherogenic role by suppressing the formation of human macrophage foam cells. H₂S inhibits the formation of macrophage-derived foam cells, which is a crucial event in the development of atherosclerosis, by downregulating CD36, SR-A, and ACAT-1 expression and inhibiting oxidized low-density lipoprotein (oxLDL) binding and uptake of macrophages (66, 67). In addition to its important role in preventing atherosclerosis, H₂S has also direct benefits for coronary heart disease (CHD) patients. Plasma H₂S levels in patients with CHD show a significant inverse correlation with the severity of CHD and changes in the coronary artery (90). Moreover, providing H₂S balneotherapy to CHD patients has been shown to result in significant prolongation of stress bicycle exercise. In the hot climate of arid zones, use of moderate H₂S baths raises the tolerance of CHD patients to exercise, attenuates clinical manifestations of CHD, and consequently reduces daily nitrate need (91). Additionally, stem cell transplantation has become a promising therapeutic approach for

treatment of myocardial infarction (MI). However, poor survival of the donor cells after transplantation has restricted its therapeutic efficacy. H₂S has been applied to inhibit cell apoptosis and promote cell survival in such cases. It has been demonstrated that H₂S preconditioning effectively promotes stem cell survival under conditions of ischemic injury and helps cardiac repair after MI (92).

Degenerative diseases of the central nervous system. Parkinson's disease (PD) is a neurodegenerative disease characterized by progressive loss of dopaminergic neurons in the substantia nigra (SN). In a 6-hydroxydopamine (6-OHDA)-induced PD rat model, the endogenous H₂S level has been found to be markedly reduced in the SN. However, H₂S treatment can specifically inhibit 6-OHDA-evoked NADPH oxidase activation, oxygen consumption, and microglial activation in the SN, and accumulation of proinflammatory factors in the striatum (68). PD is one of the most common neurodegenerative diseases with various manifestations, among which cognitive deficiency, namely, dementia, has a prominent role. Dementia is usually ascribed to changes in the nucleus basalis of Meynert and the cerebral cortex (93). H₂S has also been suggested to attenuate vascular dementia injury via inhibition of apoptosis by markedly improving the ratio of Bcl-2 to Bax, upregulating Bcl-2 expression, and downregulating Bax expression (69).

Alzheimer's disease (AD) is the most common form of demen-

TABLE 2 Effects of H₂S or its donors on age-associated diseases^a

Age-associated disease	Exptl model	H ₂ S level	Cellular response elicited by H ₂ S or its donors	Reference(s)
Hypertension	Spontaneously hypertensive rats	↓	Relaxing vascular muscle cell by involving different ion channels	65
Atherosclerotic disease	Human monocyte-derived macrophages	↓	Inhibiting foam cell formation by downregulating CD36, SR-A, and ACAT1 expression via the K _{ATP} -ERK1/2 pathway	66, 67
PD	6-OHDA-induced PD rat	↓	Inhibiting NADPH oxidase activation and oxygen consumption; inhibiting accumulation proinflammatory factors via NF-κB pathway; inhibiting neuronal apoptosis by improving Bcl-2/Bax	68, 69
AD	Amyloid β-induced cell toxicity in murine BV-2 microglial cells	↓	Inhibition of inflammation; promotion of cell growth and preservation of mitochondrial function in a p38- and JNK-MAPK-dependent manner	70, 71, 72
Diabetes	Streptozotocin-induced diabetes in mice	In pancreas, ↑	Stimulating β-cell apoptosis and inducing K _{ATP} channel activity	73, 74, 75, 76
Prostate cancer	PC-3 cells (a human prostate cancer cell line)	In plasma, ↓ ?	Protecting diabetic vascular endothelial cells Inhibiting PC-3 cells viability by activating p38 MAPK and JNK	77 78
ER(-) breast cancer	Mice with human ER(-) breast cancer xenografts	?	Suppressing the growth of cancer cells by induction of G ₀ /G ₁ arrest and apoptosis; downregulation of NF-κB; reduction of thioredoxin reductase activity; increased levels of reactive oxygen species	79
Colon cancer	HT-29 human colon cancer cells	?	Inhibiting cell proliferation by reducing PCNA expression; inducing G ₀ /G ₁ cell cycle arrest and apoptosis	80

^a PD, Parkinson's disease; AD, Alzheimer's disease; ER(-), estrogen receptor negative; 6-OHDA, 6-hydroxydopamine; SR-A, scavenger receptor A; ACAT1, acyl coenzyme A-cholesterol acyltransferase; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinases; PCNA, proliferating cell nuclear antigen.

tia. AD initially targets memory and progressively destroys the mind (94). This disease is pathologically characterized by the accumulation of senile plaques containing activated microglia and amyloid beta peptides (Aβeta) (95). As mentioned previously, endogenous H₂S is predominantly produced in the brain from cysteine by CBS (5, 96). Endogenous levels of H₂S of between 50 and 160 μM are detected in the brains of humans (40). In the brains of AD patients, lower levels of H₂S as well as accumulation of homocysteine (Hcy), a strong risk factor for the development of Alzheimer's disease (AD), are observed (71, 72). Neurotoxicity of elevated Hcy is associated with inhibition of endogenous H₂S generation and downregulation of expression and activity of CBS in PC12 cells, which is mediated by extracellular signal-regulated kinase 1 and 2 (ERK1/2) activation. It has been suggested that H₂S could reduce neurotoxicity induced by Hcy and that enhancement of H₂S synthesis may be a useful therapeutic strategy against Hcy-induced AD (97). Accordingly, Liu and Bian have demonstrated that H₂S demonstrates protective effects against Aβeta-induced cell injury by inhibiting inflammation, promoting cell growth, and preserving mitochondrial function in a p38- and Jun N-terminal protein kinase (JNK)-mitogen-activated protein kinase (MAPK)-dependent manner (70). Moreover, H₂S can protect neurons from oxidative stress, which is responsible for neuronal damage and degeneration in AD. H₂S protects neurons against glutamate-mediated oxidative stress by enhancing the activities of γ-GCS and cystine transport, which results in incremental changes of glutathione levels (98). These findings suggest that H₂S is a promising therapeutic target for treating neurodegenerative diseases.

Diabetes. Diabetes is a chronic metabolic disease with influence on the metabolism of carbohydrates and other nutrients. The pathogenesis of diabetes is associated with decreased functional beta cell mass and increased activities of K_{ATP} channels in pancre-

atic beta cells (99, 100). It has been reported that in streptozotocin-induced diabetes in mice, pancreatic H₂S production and CSE activity are significantly upregulated (73, 76). Similarly, it has also been found that pancreatic CSE expression and H₂S production are higher in Zucker diabetic fatty (ZDF) rats than in Zucker fatty and Zucker lean rats (101). Enhanced endogenous production of H₂S in diabetes can induce apoptosis of insulin-secreting beta cells by enhancing endoplasmic reticulum (ER) stress via p38 MAPK activation and also stimulate K_{ATP} channels in insulin-secreting cells (73–75). These results imply that H₂S at high concentrations contributes to the pathogenesis of diabetes mellitus.

Diabetes mellitus is also characterized by the resistance of peripheral tissues to insulin (102, 103). L-Cysteine which is synthesized from methionine is a main precursor of H₂S. However, adipose tissue is an important organ of methionine metabolism (104) and is also an insulin-sensitive organ that mediates glucose uptake and metabolism. With age, the endogenous CSE/H₂S system is upregulated in adipose tissues. Increased H₂S in adipose tissues inhibit basal or insulin-stimulated glucose metabolism and regulate insulin sensitivity. This suggests that H₂S may be a novel insulin resistance regulator (105). Additionally, Kaneko et al. suggested that elevation of the H₂S levels as a result of L-cysteine metabolism may inhibit insulin release from isolated mouse islets and the mouse β-cell line MIN6 under diabetic conditions (11). In ZDF rats, abnormally high pancreatic production of H₂S has been reported to suppress insulin release (101). These findings indicate that high concentrations of H₂S in pancreas could have deleterious effects on the development of diabetes and that new therapeutic measures for diabetes may involve inhibiting endogenous H₂S production from pancreas.

In contrast, Jain et al. have reported that blood H₂S levels are significantly lower in type 2 diabetes patients than in age-matched healthy subjects and in streptozotocin-treated diabetic rats than in

control Sprague-Dawley rats. Low blood H₂S levels may contribute to the vascular inflammation observed in diabetes because supplementation with H₂S can prevent inflammatory factor interleukin-8 (IL-8) and monocyte chemoattractant protein 1 (MCP-1) secretion by monocytes cultured in high-glucose medium (77). It has also been observed that H₂S levels in plasma and aortic tissue are progressively reduced in nonobese diabetic (NOD) mice. This suggests that reduced endogenous H₂S production is associated with diabetes-related endothelial dysfunction in NOD mice (106). Endothelial dysfunction plays a pathogenic role in the development of diabetic vascular complications. However, protective effects of H₂S on the endothelial cells under high-glucose conditions have also been observed. Pretreatment with NaHS (50 μmol/liter) protects against high-glucose-induced apoptosis in endothelial cells by increasing SOD activity, decreasing ROS generation and malondialdehyde levels, and downregulating the Bax/Bcl-2 ratio (107). These findings are consistent with those of Suzuki et al. showing that *in vitro* hyperglycemia is associated with increased H₂S degradation caused by mitochondrial ROS overproduction and that H₂S replacement has cytoprotective effects on endothelial cells in hyperglycemia *in vitro*. H₂S protects against the development of hyperglycemia-induced endothelial dysfunction by attenuating the hyperglycemia-induced enhancement of ROS formation, attenuating nuclear DNA injury, reducing the activation of the nuclear enzyme poly(ADP-ribose) polymerase, and improving cellular viability (108).

Furthermore, inhibiting ACE, a Zn-dependent enzyme, has been recommended to prevent diabetic nephropathy (109). The H₂S level and CSE expression in the renal cortex of diabetic rats have been shown to be significantly decreased (110). As indicated earlier, H₂S at a physiological concentration exhibits direct inhibitory action on ACE activity in human umbilical vein endothelial cells by interfering with the Zn²⁺ in the active center of the enzyme (62). Thus, it appears that H₂S could also protect against diabetes nephropathy by functioning as an ACE inhibitor. These findings imply that H₂S at normal physiological concentrations may have beneficial effects on the control of diabetes owing to its anti-inflammatory and antioxidative roles. Therefore, inhibiting pancreatic H₂S biosynthesis may be a potential approach to protect β cells from death during the induction phase of diabetes, whereas supplementation with H₂S could be considered a potential approach to maintain diabetic blood vessel potency (111).

Cancer. The slow-releasing H₂S donor GYY4137 can kill seven different human cancer cell lines (HeLa, HCT-116, Hep G2, HL-60, MCF-7, MV4-11, and U2OS) in a concentration-dependent manner. This indicates that H₂S could be a potential anticancer agent (112). Moreover, H₂S-releasing nonsteroidal anti-inflammatory drugs (HS-NSAID) composed of a traditional NSAID to which an H₂S-releasing moiety is covalently attached have significant anti-inflammatory properties. It has been shown that HS-NSAID can inhibit the growth of all cancer cells, such as human colon, breast, pancreatic, prostate, lung, and leukemia cancer cells, by inhibiting cell proliferation, inducing apoptosis, and causing G₀/G₁ cell cycle block. These data indicate that H₂S may have potential antiproliferative activity against various human cancer cells (113).

Sulforaphane, a sulfur-containing compound with properties against prostate cancer, can release a large amount of H₂S. Pei et al. showed that H₂S can decrease the viability of PC-3 cells (a human prostate cancer cell line) in a dose-dependent manner (78). Im-

portantly, both CSE and CBS are expressed in the prostate. Thus, H₂S-releasing diets or drugs may be beneficial in the treatment of prostate cancer. Similarly, H₂S-releasing aspirin, a novel and safer derivative of aspirin, has shown promise as an anticancer agent against hormone-independent estrogen receptor-negative breast cancers by inhibiting cell proliferation, inducing apoptosis, and decreasing NF-κB levels (79). Moreover, NOSH-aspirin, a NO- and H₂S-releasing agent, has been found to inhibit colon cancer growth by inhibiting cell proliferation, inducing apoptosis, and causing G₀/G₁ cell cycle block (80). Overall, these results indirectly demonstrate that H₂S has strong anticancer potential that merits further evaluation.

PERSPECTIVES

The findings discussed in this review strongly argue in favor of a role for H₂S in aging and age-associated diseases. However, the mechanisms of action of this role of H₂S have not yet been sufficiently characterized and await elucidation by further studies. A better understanding of the roles of H₂S in aging can provide insights into potential therapeutic interventions against aging and reduce age-associated diseases. More specifically, data available so far strongly suggest that H₂S may become the next potent preventive and therapeutic agent for preventing and ameliorating the symptoms of aging and age-associated diseases, and this should be addressed in future studies.

ACKNOWLEDGMENTS

This work was supported by grants from the National Natural Science Foundation of China (81170277 to Z.-S.J.), by the Special Research Fund for the Doctoral Program of Higher Education of China Project (20124324110003 to Z.-S.J.), and by the Aid Program for Science and Technology Innovative Research Team in Higher Educational Institutions of Hunan Province.

REFERENCES

1. Harman D. 1956. Aging: a theory based on free radical and radiation chemistry. *J. Gerontol.* 11:298–300.
2. Fusco D, Colloca G, Lo Monaco MR, Cesari M. 2007. Effects of antioxidant supplementation on the aging process. *Clin. Interv. Aging* 2:377–387.
3. Chen YH, Yao WZ, Geng B, Ding YL, Lu M, Zhao MW, Tang CS. 2005. Endogenous hydrogen sulfide in patients with COPD. *Chest* 128: 3205–3211.
4. Perna AF, Lanza D, Sepe I, Raiola I, Capasso R, De Santo NG, Ingrosso D. 2011. Hydrogen sulfide, a toxic gas with cardiovascular properties in uremia: how harmful is it? *Blood Purif.* 31:102–106.
5. Wang R. 2002. Two's company, three's a crowd: can H₂S be the third endogenous gaseous transmitter? *FASEB J.* 16:1792–1798.
6. Abe K, Kimura H. 1996. The possible role of hydrogen sulfide as an endogenous neuromodulator. *J. Neurosci.* 16:1066–1071.
7. Hosoki R, Matsuki N, Kimura H. 1997. The possible role of hydrogen sulfide as an endogenous smooth muscle relaxant in synergy with nitric oxide. *Biochem. Biophys. Res. Commun.* 237:527–531.
8. Diwakar L, Ravindranath V. 2007. Inhibition of cystathionine-gamma-lyase leads to loss of glutathione and aggravation of mitochondrial dysfunction mediated by excitatory amino acid in the CNS. *Neurochem. Int.* 50:418–426.
9. Enokido Y, Suzuki E, Iwasawa K, Namekata K, Okazawa H, Kimura H. 2005. Cystathionine beta-synthase, a key enzyme for homocysteine metabolism, is preferentially expressed in the radial glia/astrocyte lineage of developing mouse CNS. *FASEB J.* 19:1854–1856.
10. Ichinohe A, Kanaumi T, Takashima S, Enokido Y, Nagai Y, Kimura H. 2005. Cystathionine beta-synthase is enriched in the brains of Down's patients. *Biochem. Biophys. Res. Commun.* 338:1547–1550.
11. Kaneko Y, Kimura Y, Kimura H, Niki I. 2006. L-Cysteine inhibits insulin release from the pancreatic beta-cell: possible involvement of

- metabolic production of hydrogen sulfide, a novel gasotransmitter. *Diabetes* 55:1391–1397.
12. Patel P, Vatish M, Heptinstall J, Wang R, Carson RJ. 2009. The endogenous production of hydrogen sulphide in intrauterine tissues. *Reprod. Biol. Endocrinol.* 7:10. doi:10.1186/1477-7827-7-10.
 13. Vitvitsky V, Thomas M, Ghorpade A, Gendelman HE, Banerjee R. 2006. A functional transsulfuration pathway in the brain links to glutathione homeostasis. *J. Biol. Chem.* 281:35785–35793.
 14. Kimura H. 2000. Hydrogen sulfide induces cyclic AMP and modulates the NMDA receptor. *Biochem. Biophys. Res. Commun.* 267:129–133.
 15. Robert K, Vialard F, Thiery E, Toyama K, Sinet PM, Janel N, London J. 2003. Expression of the cystathionine beta synthase (CBS) gene during mouse development and immunolocalization in adult brain. *J. Histochem. Cytochem.* 51:363–371.
 16. Geng B, Yang J, Qi Y, Zhao J, Pang Y, Du J, Tang C. 2004. H₂S generated by heart in rat and its effects on cardiac function. *Biochem. Biophys. Res. Commun.* 313:362–368.
 17. Zhao W, Zhang J, Lu Y, Wang R. 2001. The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. *EMBO J.* 20:6008–6016.
 18. Shibuya N, Mikami Y, Kimura Y, Nagahara N, Kimura H. 2009. Vascular endothelium expresses 3-mercaptopyruvate sulfurtransferase and produces hydrogen sulfide. *J. Biochem.* 146:623–626.
 19. Mustafa AK, Sikka G, Gazi SK, Steppan J, Jung SM, Bhunia AK, Barodka VM, Gazi FK, Barrow RK, Wang R, Amzel LM, Berkowitz DE, Snyder SH. 2011. Hydrogen sulfide as endothelium-derived hyperpolarizing factor sulfhydrates potassium channels. *Circ. Res.* 109:1259–1268.
 20. Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K, Meng Q, Mustafa AK, Mu W, Zhang S, Snyder SH, Wang R. 2008. H₂S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. *Science* 322:587–590.
 21. Liu C, Gu X, Zhu YZ. 2010. Synthesis and biological evaluation of novel leonurine-SPRC conjugate as cardioprotective agents. *Bioorg. Med. Chem. Lett.* 20:6942–6946.
 22. Taniguchi S, Kang L, Kimura T, Niki I. 2011. Hydrogen sulphide protects mouse pancreatic beta-cells from cell death induced by oxidative stress, but not by endoplasmic reticulum stress. *Br. J. Pharmacol.* 162:1171–1178.
 23. Zhang H, Zhang A, Guo C, Shi C, Zhang Y, Liu Q, Sparatore A, Wang C. 2011. S-diclofenac protects against doxorubicin-induced cardiomyopathy in mice via ameliorating cardiac gap junction remodeling. *PLoS One* 6:e26441. doi:10.1371/journal.pone.0026441.
 24. Hu LF, Wong PT, Moore PK, Bian JS. 2007. Hydrogen sulfide attenuates lipopolysaccharide-induced inflammation by inhibition of p38 mitogen-activated protein kinase in microglia. *J. Neurochem.* 100:1121–1128.
 25. Jin HF, Liang C, Liang JM, Tang CS, Du JB. 2008. Effects of hydrogen sulfide on vascular inflammation in pulmonary hypertension induced by high pulmonary blood flow: experiment with rats. *Zhonghua Yi Xue Za Zhi* 88:2235–2239. (In Chinese.)
 26. Kim KM, Pae HO, Zhung M, Ha HY, Ha YA, Chai KY, Cheong YK, Kim JM, Chung HT. 2008. Involvement of anti-inflammatory heme oxygenase-1 in the inhibitory effect of curcumin on the expression of pro-inflammatory inducible nitric oxide synthase in RAW264.7 macrophages. *Biomed. Pharmacother.* 62:630–636.
 27. Oh GS, Pae HO, Lee BS, Kim BN, Kim JM, Kim HR, Jeon SB, Jeon WK, Chae HJ, Chung HT. 2006. Hydrogen sulfide inhibits nitric oxide production and nuclear factor-kappaB via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide. *Free Radic. Biol. Med.* 41:106–119.
 28. Pan LL, Liu XH, Gong QH, Wu D, Zhu YZ. 2011. Hydrogen sulfide attenuated tumor necrosis factor-alpha-induced inflammatory signaling and dysfunction in vascular endothelial cells. *PLoS One* 6:e19766. doi:10.1371/journal.pone.0019766.
 29. Calvert JW, Coetzee WA, Lefer DJ. 2010. Novel insights into hydrogen sulfide-mediated cytoprotection. *Antioxid. Redox Signal.* 12:1203–1217.
 30. Sen N, Paul BD, Gadalla MM, Mustafa AK, Sen T, Xu R, Kim S, Snyder SH. 2012. Hydrogen sulfide-linked sulfhydration of NF-kappaB mediates its antiapoptotic actions. *Mol. Cell* 45:13–24.
 31. Tan G, Pan S, Li J, Dong X, Kang K, Zhao M, Jiang X, Kanwar JR, Qiao H, Jiang H, Sun X. 2011. Hydrogen sulfide attenuates carbon tetrachloride-induced hepatotoxicity, liver cirrhosis and portal hypertension in rats. *PLoS One* 6:e25943. doi:10.1371/journal.pone.0025943.
 32. Wang MJ, Cai WJ, Zhu YC. 2010. Mechanisms of angiogenesis: role of hydrogen sulphide. *Clin. Exp. Pharmacol. Physiol.* 37:764–771.
 33. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, Howitz KT, Gorospe M, de Cabo R, Sinclair DA. 2004. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. *Science* 305:390–392.
 34. Harman D. 1981. The aging process. *Proc. Natl. Acad. Sci. U. S. A.* 78:7124–7128.
 35. Harman D. 1988. Free radicals in aging. *Mol. Cell. Biochem.* 84:155–161.
 36. Benedetti S, Benvenuti F, Nappi G, Fortunati NA, Marino L, Aureli T, De Luca S, Pagliarani S, Canestrari F. 2009. Antioxidative effects of sulfurous mineral water: protection against lipid and protein oxidation. *Eur. J. Clin. Nutr.* 63:106–112.
 37. Franssen M, Nordgren M, Wang B, Apanasets O. 2012. Role of peroxisomes in ROS/RNS-metabolism: implications for human disease. *Biochim. Biophys. Acta* 1822:1363–1373.
 38. Tyagi N, Moshal KS, Sen U, Vacek TP, Kumar M, Hughes WM, Jr, Kundu S, Tyagi SC. 2009. H₂S protects against methionine-induced oxidative stress in brain endothelial cells. *Antioxid. Redox Signal.* 11:25–33.
 39. van der Vliet A, Eiserich JP, O'Neill CA, Halliwell B, Cross CE. 1995. Tyrosine modification by reactive nitrogen species: a closer look. *Arch. Biochem. Biophys.* 319:341–349.
 40. Whiteman M, Armstrong JS, Chu SH, Jia-Ling S, Wong BS, Cheung NS, Halliwell B, Moore PK. 2004. The novel neuromodulator hydrogen sulfide: an endogenous peroxynitrite 'scavenger'? *J. Neurochem.* 90:765–768.
 41. Whiteman M, Li L, Kostetski I, Chu SH, Siau JL, Bhatia M, Moore PK. 2006. Evidence for the formation of a novel nitrosothiol from the gaseous mediators nitric oxide and hydrogen sulphide. *Biochem. Biophys. Res. Commun.* 343:303–310.
 42. Kimura Y, Goto Y, Kimura H. 2010. Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria. *Antioxid. Redox Signal.* 12:1–13.
 43. Weindruch R. 1996. The retardation of aging by caloric restriction: studies in rodents and primates. *Toxicol. Pathol.* 24:742–745.
 44. Harman D. 1972. The biologic clock: the mitochondria? *J. Am. Geriatr. Soc.* 20:145–147.
 45. Liu Y, Kalogeris T, Wang M, Zuidema MY, Wang Q, Dai H, Davis MJ, Hill MA, Korthuis RJ. 2012. Hydrogen sulfide preconditioning or neutrophil depletion attenuates ischemia-reperfusion-induced mitochondrial dysfunction in rat small intestine. *Am. J. Physiol. Gastrointest. Liver Physiol.* 302:G44–G54.
 46. Sun WH, Liu F, Chen Y, Zhu YC. 2012. Hydrogen sulfide decreases the levels of ROS by inhibiting mitochondrial complex IV and increasing SOD activities in cardiomyocytes under ischemia/reperfusion. *Biochem. Biophys. Res. Commun.* 421:164–169.
 47. Brachmann CB, Sherman JM, Devine SE, Cameron EE, Pillus L, Boeke JD. 1995. The SIR2 gene family, conserved from bacteria to humans, functions in silencing, cell cycle progression, and chromosome stability. *Genes Dev.* 9:2888–2902.
 48. Kaerberlein M, McVey M, Guarente L. 1999. The SIR2/3/4 complex and SIR2 alone promote longevity in *Saccharomyces cerevisiae* by two different mechanisms. *Genes Dev.* 13:2570–2580.
 49. Lee SS, Kennedy S, Tolonen AC, Ruvkun G. 2003. DAF-16 target genes that control *C. elegans* life-span and metabolism. *Science* 300:644–647.
 50. Tissenbaum HA, Guarente L. 2001. Increased dosage of a sir-2 gene extends lifespan in *Caenorhabditis elegans*. *Nature* 410:227–230.
 51. Frye RA. 2000. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. *Biochem. Biophys. Res. Commun.* 273:793–798.
 52. Shang Z, Lu C, Chen S, Hua L, Qian R. 2012. Effect of H₂S on the circadian rhythm of mouse hepatocytes. *Lipids Health Dis.* 11:23.
 53. Miller DL, Roth MB. 2007. Hydrogen sulfide increases thermotolerance and lifespan in *Caenorhabditis elegans*. *Proc. Natl. Acad. Sci. U. S. A.* 104:20618–20622.
 54. Predmore BL, Alendy MJ, Ahmed KI, Leeuwenburgh C, Julian D. 2010. The hydrogen sulfide signaling system: changes during aging and the benefits of caloric restriction. *Age (Dordr)* 32:467–481.
 55. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski

- MP, Gygi SP, Sinclair DA, Alt FW, Greenberg ME. 2004. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. *Science* 303:2011–2015.
56. Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmman H, Taussig R, Brown AL, Kim MK, Beaven MA, Burgin AB, Manganiello V, Chung JH. 2012. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. *Cell* 148:421–433.
 57. Bucci M, Papapetropoulos A, Vellecco V, Zhou Z, Pyriochou A, Roussos C, Roviezzo F, Brancaleone V, Cirino G. 2010. Hydrogen sulfide is an endogenous inhibitor of phosphodiesterase activity. *Arterioscler. Thromb. Vasc. Biol.* 30:1998–2004.
 58. Yamamoto M, Clark JD, Pastor JV, Gurnani P, Nandi A, Kurosu H, Miyoshi M, Ogawa Y, Castrillon DH, Rosenblatt KP, Kuro-o M. 2005. Regulation of oxidative stress by the anti-aging hormone klotho. *J. Biol. Chem.* 280:38029–38034.
 59. Château MT, Araiz C, Descamps S, Galas S. 2010. Klotho interferes with a novel FGF-signalling pathway and insulin/Igf-like signalling to improve longevity and stress resistance in *Caenorhabditis elegans*. *Aging (Albany NY)* 2:567–581.
 60. Mitani H, Ishizaka N, Aizawa T, Ohno M, Usui S, Suzuki T, Amaki T, Mori I, Nakamura Y, Sato M, Nangaku M, Hirata Y, Nagai R. 2002. In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage. *Hypertension* 39:838–843.
 61. Yoon HE, Ghee JY, Piao S, Song JH, Han DH, Kim S, Ohashi N, Kobori H, Kuro-o M, Yang CW. 2011. Angiotensin II blockade upregulates the expression of Klotho, the anti-ageing gene, in an experimental model of chronic cyclosporine nephropathy. *Nephrol. Dial. Transplant.* 26:800–813.
 62. Laggner H, Hermann M, Esterbauer H, Muellner MK, Exner M, Gmeiner BM, Kapiotis S. 2007. The novel gaseous vasorelaxant hydrogen sulfide inhibits angiotensin-converting enzyme activity of endothelial cells. *J. Hypertens.* 25:2100–2104.
 63. Zhao X, Zhang LK, Zhang CY, Zeng XJ, Yan H, Jin HF, Tang CS, Du JB. 2008. Regulatory effect of hydrogen sulfide on vascular collagen content in spontaneously hypertensive rats. *Hypertens. Res.* 31:1619–1630.
 64. Lu M, Liu YH, Goh HS, Wang JJ, Yong QC, Wang R, Bian JS. 2010. Hydrogen sulfide inhibits plasma renin activity. *J. Am. Soc. Nephrol.* 21:993–1002.
 65. Du J, Yan H, Tang C. 2003. Endogenous H₂S is involved in the development of spontaneous hypertension. *Beijing Da Xue Xue Bao* 35:102. (In Chinese.)
 66. Laggner H, Muellner MK, Schreier S, Sturm B, Hermann M, Exner M, Gmeiner BM, Kapiotis S. 2007. Hydrogen sulphide: a novel physiological inhibitor of LDL atherogenic modification by HOCl. *Free Radic. Res.* 41:741–747.
 67. Zhao ZZ, Wang Z, Li GH, Wang R, Tan JM, Cao X, Suo R, Jiang ZS. 2011. Hydrogen sulfide inhibits macrophage-derived foam cell formation. *Exp. Biol. Med. (Maywood)* 236:169–176.
 68. Hu LF, Lu M, Tiong CX, Dawe GS, Hu G, Bian JS. 2010. Neuroprotective effects of hydrogen sulfide on Parkinson's disease rat models. *Aging Cell* 9:135–146.
 69. Zhang LM, Jiang CX, Liu DW. 2009. Hydrogen sulfide attenuates neuronal injury induced by vascular dementia via inhibiting apoptosis in rats. *Neurochem. Res.* 34:1984–1992.
 70. Liu YY, Bian JS. 2010. Hydrogen sulfide protects amyloid-beta induced cell toxicity in microglia. *J. Alzheimers Dis.* 22:1189–1200.
 71. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA. 2002. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. *N. Engl. J. Med.* 346:476–483.
 72. Tang XQ, Shen XT, Huang YE, Ren YK, Chen RQ, Hu B, He JQ, Yin WL, Xu JH, Jiang ZS. 2010. Hydrogen sulfide antagonizes homocysteine-induced neurotoxicity in PC12 cells. *Neurosci. Res.* 68:241–249.
 73. Yang G, Tang G, Zhang L, Wu L, Wang R. 2011. The pathogenic role of cystathionine gamma-lyase/hydrogen sulfide in streptozotocin-induced diabetes in mice. *Am. J. Pathol.* 179:869–879.
 74. Yang G, Yang W, Wu L, Wang R. 2007. H₂S, endoplasmic reticulum stress, and apoptosis of insulin-secreting beta cells. *J. Biol. Chem.* 282:16567–16576.
 75. Yang W, Yang G, Jia X, Wu L, Wang R. 2005. Activation of KATP channels by H₂S in rat insulin-secreting cells and the underlying mechanisms. *J. Physiol.* 569:519–531.
 76. Yusuf M, Kwong Huat BT, Hsu A, Whiteman M, Bhatia M, Moore PK. 2005. Streptozotocin-induced diabetes in the rat is associated with enhanced tissue hydrogen sulfide biosynthesis. *Biochem. Biophys. Res. Commun.* 333:1146–1152.
 77. Jain SK, Bull R, Rains JL, Bass PF, Levine SN, Reddy S, McVie R, Bocchini JA. 2010. Low levels of hydrogen sulfide in the blood of diabetic patients and streptozotocin-treated rats causes vascular inflammation? *Antioxid. Redox Signal.* 12:1333–1337.
 78. Pei Y, Wu B, Cao Q, Wu L, Yang G. 2011. Hydrogen sulfide mediates the anti-survival effect of sulforaphane on human prostate cancer cells. *Toxicol. Appl. Pharmacol.* 257:420–428.
 79. Chattopadhyay M, Kodela R, Nath N, Barsegian A, Boring D, Kashfi K. 2012. Hydrogen sulfide-releasing aspirin suppresses NF-kappaB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo. *Biochem. Pharmacol.* 83:723–732.
 80. Chattopadhyay M, Kodela R, Olson KR, Kashfi K. 2012. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model. *Biochem. Biophys. Res. Commun.* 419:523–528.
 81. Fukutomi M, Kario K. 2010. Aging and hypertension. *Expert Rev. Cardiovasc. Ther.* 8:1531–1539.
 82. Zhong G, Chen F, Cheng Y, Tang C, Du J. 2003. The role of hydrogen sulfide generation in the pathogenesis of hypertension in rats induced by inhibition of nitric oxide synthase. *J. Hypertens.* 21:1879–1885.
 83. Touyz RM. 2000. Molecular and cellular mechanisms regulating vascular function and structure—implications in the pathogenesis of hypertension. *Can. J. Cardiol.* 16:1137–1146.
 84. Cheng Y, Ndisang JF, Tang G, Cao K, Wang R. 2004. Hydrogen sulfide-induced relaxation of resistance mesenteric artery beds of rats. *Am. J. Physiol. Heart Circ. Physiol.* 287:H2316–H2323.
 85. Baukowitz T, Schulte U, Oliver D, Herlitz S, Krauter T, Tucker SJ, Ruppertsberg JP, Fakler B. 1998. PIP₂ and PIP as determinants for ATP inhibition of KATP channels. *Science* 282:1141–1144.
 86. Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry GJ, Shi L, Qiu D, Benson G, Pearl RG, Kao PN. 2003. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. *Circulation* 108:1640–1645.
 87. Du J, Hui Y, Cheung Y, Bin G, Jiang H, Chen X, Tang C. 2004. The possible role of hydrogen sulfide as a smooth muscle cell proliferation inhibitor in rat cultured cells. *Heart Vessels* 19:75–80.
 88. Lusis AJ. 2000. Atherosclerosis. *Nature* 407:233–241.
 89. Lynn EG, Austin RC. 2011. Hydrogen sulfide in the pathogenesis of atherosclerosis and its therapeutic potential. *Expert Rev. Clin. Pharmacol.* 4:97–108.
 90. Jiang HL, Wu HC, Li ZL, Geng B, Tang CS. 2005. Changes of the new gaseous transmitter H₂S in patients with coronary heart disease. *Di Yi Jun Yi Da Xue Xue Bao* 25:951–954. (In Chinese.)
 91. Zunnunov ZR. 2004. Efficacy and safety of hydrogen sulfide balneotherapy in ischemic heart disease the arid zone. *Ter. Arkh.* 76:15–18. (In Russian.)
 92. Xie X, Sun A, Zhu W, Huang Z, Hu X, Jia J, Zou Y, Ge J. 2012. Transplantation of mesenchymal stem cells preconditioned with hydrogen sulfide enhances repair of myocardial infarction in rats. *Tohoku J. Exp. Med.* 226:29–36.
 93. Korczyn AD. 2010. Vascular contribution to dementia in Parkinson's disease. *Neurodegener. Dis.* 7:127–130.
 94. Kidd PM. 2008. Alzheimer's disease, amnesic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. *Altern. Med. Rev.* 13:85–115.
 95. Hampel H. 2013. Amyloid-beta and cognition in aging and Alzheimer's disease: molecular and neurophysiological mechanisms. *J. Alzheimers Dis.* 33:S79–S86.
 96. Moore PK, Bhatia M, Mochhala S. 2003. Hydrogen sulfide: from the smell of the past to the mediator of the future? *Trends Pharmacol. Sci.* 24:609–611.
 97. Tang XQ, Shen XT, Huang YE, Chen RQ, Ren YK, Fang HR, Zhuang YY, Wang CY. 2011. Inhibition of endogenous hydrogen sulfide generation is associated with homocysteine-induced neurotoxicity: role of ERK1/2 activation. *J. Mol. Neurosci.* 45:60–67.
 98. Kimura Y, Kimura H. 2004. Hydrogen sulfide protects neurons from oxidative stress. *FASEB J.* 18:1165–1167.
 99. Koster JC, Permutt MA, Nichols CG. 2005. Diabetes and insulin secre-

- tion: the ATP-sensitive K⁺ channel (K ATP) connection. *Diabetes* 54: 3065–3072.
100. Mathis D, Vence L, Benoist C. 2001. beta-cell death during progression to diabetes. *Nature* 414:792–798.
 101. Wu L, Yang W, Jia X, Yang G, Duridanova D, Cao K, Wang R. 2009. Pancreatic islet overproduction of H₂S and suppressed insulin release in Zucker diabetic rats. *Lab. Invest.* 89:59–67.
 102. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. 1992. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. *Lancet* 340:925–929.
 103. Weyer C, Tataranni PA, Bogardus C, Pratley RE. 2001. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. *Diabetes Care* 24:89–94.
 104. Feller DD, Feist E. 1963. Conversion of methionine and threonine to fatty acids by adipose tissue. *Can. J. Biochem. Physiol.* 41:269–273.
 105. Feng X, Chen Y, Zhao J, Tang C, Jiang Z, Geng B. 2009. Hydrogen sulfide from adipose tissue is a novel insulin resistance regulator. *Biochem. Biophys. Res. Commun.* 380:153–159.
 106. Brancaleone V, Roviezzo F, Vellecco V, De Gruttola L, Bucci M, Cirino G. 2008. Biosynthesis of H₂S is impaired in non-obese diabetic (NOD) mice. *Br. J. Pharmacol.* 155:673–680.
 107. Guan Q, Zhang Y, Yu C, Liu Y, Gao L, Zhao J. 2012. Hydrogen sulfide protects against high-glucose-induced apoptosis in endothelial cells. *J. Cardiovasc. Pharmacol.* 59:188–193.
 108. Suzuki K, Olah G, Modis K, Coletta C, Kulp G, Gero D, Szoleczky P, Chang T, Zhou Z, Wu L, Wang R, Papapetropoulos A, Szabo C. 2011. Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial function. *Proc. Natl. Acad. Sci. U. S. A.* 108:13829–13834.
 109. Solski LV, Longyhore DS. 2008. Prevention of type 2 diabetes mellitus with angiotensin-converting-enzyme inhibitors. *Am. J. Health Syst. Pharm.* 65:935–940.
 110. Yuan P, Xue H, Zhou L, Qu L, Li C, Wang Z, Ni J, Yu C, Yao T, Huang Y, Wang R, Lu L. 2011. Rescue of mesangial cells from high glucose-induced over-proliferation and extracellular matrix secretion by hydrogen sulfide. *Nephrol. Dial. Transplant.* 26:2119–2126.
 111. Szabo C. 2012. Roles of hydrogen sulfide in the pathogenesis of diabetes mellitus and its complications. *Antioxid. Redox Signal.* 17:68–80.
 112. Lee ZW, Zhou J, Chen CS, Zhao Y, Tan CH, Li L, Moore PK, Deng LW. 2011. The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. *PLoS One* 6:e21077. doi:10.1371/journal.pone.0021077.
 113. Chattopadhyay M, Kodela R, Nath N, Dastagirzada YM, Velazquez-Martinez CA, Boring D, Kashfi K. 2012. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect. *Biochem. Pharmacol.* 83: 715–722.